Market Signal Briefing

NEW ORLEANS, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 2, 2025 to file lead plaintiff applications in a securities class action lawsuit against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH), if they purchased or otherwise acquired the Company’s securities between February 5, 2025 and July 23, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

Get Help

Molina Healthcare investors should visit us at https://claimsfiler.com/cases/nyse-moh-2/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Molina Healthcare and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On July 23, 2025, the Company reported its financial results for the second quarter ended June 30, 2025 and cut its full-year 2025 earnings guidance, disclosing that “GAAP net income was $4.75 per diluted share for the second quarter of 2025, a decrease of 8% year over year” and it “now expects its full year 2025 adjusted earnings to be no less than $19.00 per diluted share,” due to a “challenging medical cost trend environment,” including “utilization of behavioral health, pharmacy, and inpatient and outpatient services.”

On this news, the price of Molina’s shares fell $32.03, or 16.84%, to close at $158.22 per share on July 24, 2025, on unusually heavy trading volume.

The case is Hindlemann v. Molina Healthcare, Inc., et al., No. 2:25-cv-09461.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

-

Agencies advance digital-first engagement as citizens seek secure, efficient, personalized interactions, ISG Provider Lens® report says

SYDNEY--(BUSINESS WIRE)--Australia’s public sector is transforming service delivery by replacing outdated systems with tools that let agencies build services around citizen experience, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.

Public sector modernization in Australia is being driven by citizens’ expectations for secure and seamless services. By rebuilding new technology foundations, agencies are creating systems that enable lasting improvements in service quality.

Share
The 2025 ISG Provider Lens® Public Sector Services and Solutions report for Australia finds that agencies are expanding digital services to meet rising citizen expectations and improve efficiency. Citizens want digital encounters with government to be simple, reliable and personalized. Institutions are responding by modernizing infrastructure and adopting technologies that streamline processes and strengthen trust.

“Public sector modernization in Australia is being driven by citizens’ expectations for secure and seamless services,” said Michael Gale, partner and regional leader, ISG Asia Pacific. “By rebuilding new technology foundations, agencies are creating systems that enable lasting improvements in service quality.”

Research shows more than 90 percent of Australians prefer digital government interactions, but only 79 percent of service contacts occur online, ISG says. While significant progress has been made, the continuing shortfall reflects both outdated systems and fragmented data environments. Closing the gap is expected to yield more cost savings and reclaim millions of citizens’ hours. Agencies are aligning modernization efforts with the national 2030 Data and Digital Government Strategy, which sets goals for reliable, connected public services.

Outdated IT systems and siloed data continue to limit interoperability across departments, slowing decision-making and service delivery, the report says. Agencies are replacing legacy platforms with integrated solutions that support evidence-based policymaking and allow real-time collaboration. This infrastructure modernization also helps agencies meet compliance standards and protect sensitive data more effectively.

Workforce transformation is emerging alongside technology adoption in the sector, ISG says. Younger employees in Australia place a high value on digital fluency and flexible working conditions. Agencies are introducing hybrid and remote work options supported by secure infrastructure. In addition, AI, automation and fraud detection tools are streamlining operations and allowing agencies to be more responsive. These technologies increase citizens’ trust in digital services while enabling staff to focus on higher-value activities.

Public sector organizations in Australia are using technology to improve collaboration across agencies and jurisdictions to address complex challenges, the report says. Shared digital platforms and standardized data-sharing protocols enable more integrated services and create more tailored engagement options for citizens. By aligning their systems and resources, agencies position themselves better to handle issues such as climate change, cyber threats and healthcare challenges.

“Australia’s public sector will continue to increase its use of AI to optimize processes and anticipate citizens’ expectations,” said Harish B, manager and principal analyst at ISG and lead author of the report. “Service providers will play a crucial role in this evolution by helping agencies overcome structural inertia and skills shortages.”

The report also explores other technology trends influencing Australia’s public sector, including the growing focus by public agencies on cloud migration and deploying robust, scalable cybersecurity frameworks to protect citizen data and maintain system integrity.

For more insights into the technology challenges facing the Australian public sector, plus ISG’s advice for overcoming them, see the ISG Provider Lens® Focal Points briefing here.

The 2025 ISG Provider Lens® Public Sector report for Australia evaluates 34 providers across four quadrants: Strategy and Consulting Services, Managed IT Services, Business Process and Other Outsourcing Services, and Digital Transformation and Innovation Services.

The report names Accenture and Capgemini as Leaders in four quadrants each. It names AC3, IBM and Infosys as Leaders in three quadrants each. It names Probe Group as a Leader in two quadrants. Concentrix, Data#3, Deloitte, Fujitsu, KPMG, Mastek, NRI, Optus, Serco, TCS, Telstra, Unisys and Wipro are named as Leaders in one quadrant each.

In addition, Infosys is recognized as a Rising Star — a company with a “promising portfolio” and “high future potential” by ISG’s definition — in one quadrant.

In the area of customer experience, Capgemini is named the global ISG CX Star Performer for 2025 among public sector service and solution providers. Capgemini earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, which is part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.

The 2025 ISG Provider Lens® Public Sector Services and Solutions report for Australia is available to subscribers or for one-time purchase on this webpage.

About ISG Provider Lens® Research

The ISG Provider Lens® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.

More News From Information Services Group, Inc.

Back to Newsroom

Constellation Energy offers exactly what data centers and artificial intelligence players need: reliable 24/7 power.

Big tech has a big issue: Its data centers consume colossal amounts of power, and not all of it is clean.

Electricity demand in the U.S. is expected to grow about 25% by 2030, from 2023 levels, and 78% by 2050.

Enter Constellation Energy (CEG 3.96%). As the country's largest producer of carbon-free electricity, as well as its biggest provider of nuclear power, Constellation is at the center of solving this big-tech issue. The company's stock is up over 48% so far this year, and by the looks of it, it could be poised for more growth ahead. It's one of the best energy stocks bo buy right now.

Image source: Getty Images.

The bull case for Constellation Energy
When you think of utilities stocks, you may think of slow growth and dividends. But Constellation is anything but normal.

Unlike most utility companies, Constellation Energy isn't regulated. That means it sells power at market price rather than fixed, government-approved rates. When demand for electricity is high, Constellation can benefit directly. And right now, demand is booming.

Better yet, demand for clean energy is booming, which is Constellation's bread and butter. The company owns the country's largest carbon-free fleet, mostly nuclear. That has helped it lock into strategic supply agreements with big tech companies like Meta Platforms and Microsoft.

Most of Constellation's carbon-free power comes from its nuclear facililites, which has about 22.2 gigawatts of capacity. That makes Constellation not only the leader in nuclear capacity in the U.S., but also positions it nicely to profit from the AI boom, as data centers need reliable, 24/7 power.

The company's recent $26.6 billion acquisition of Calpine could also add about 25 GW of gas capacity. Management expects the deal to add about $2 billion in free cash flow per year.

Is it a buy now?
That said, Constellation trades at about 32 times forward earnings estimates, or roughly double the average multiple for the energy sector. For investors betting on the next decade of energy growth, however, it's hard to find a better energy stock to plug into.

Steven Porrello has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Constellation Energy, Meta Platforms, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

HSBC logo is seen in this illustration taken December 22, 2023. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

Oct 9 (Reuters) - HSBC

(HSBA.L), opens new tab has requested that the board of Hang Seng Bank

(0011.HK), opens new tab submit a privatisation proposal to shareholders through a scheme of arrangement under Hong Kong's Companies Ordinance, according to a joint announcement on Thursday.

Under the proposal put forward by HSBC Asia Pacific, Hang Seng Bank shares would be cancelled in exchange for a cash payment of HK$155 ($19.78) per share, valuing the transaction at approximately HK$290.74 billion.

Sign up here.

The offer is subject to adjustment for any dividends declared after the announcement date, excluding the 2025 third interim dividend.

Privatisation schemes are commonly used in Hong Kong to streamline corporate structures and reduce the costs associated with maintaining a public listing.

As a key subsidiary of HSBC, Hang Seng Bank plays a significant role in the region's banking sector, making the offer a pivotal move in further consolidating HSBC's regional presence and operations.

The offer price is final, HSBC said, adding that it does not reserve the right to revise it.

Reporting by Adwitiya Srivastava in Bengaluru; Editing by Sumana Nandy

Our Standards: The Thomson Reuters Trust Principles., opens new tab

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Encompass Health Corporation (NYSE: EHC) resulting from allegations that Encompass Health may have issued materially misleading business information to the investing public.

So what: If you purchased Encompass Health securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=44051https://rosenlegal.com/submit-form/?case_id=41168 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On July 15, 2025, The New York Times published an article entitled "Even Grave Errors at Rehab Hospitals Go Unpenalized and Undisclosed." The article stated that "[r]ehab hospitals that help people recover from major surgeries and injuries have become a highly lucrative slice of the health care business. But federal data and inspection reports show that some run by the dominant company, Encompass Health Corporation, [. . .] have had rare but serious incidents of patient harm and perform below average on two key safety measures tracked by Medicare."

On this news, the price of Encompass Health stock fell 10.3% on July 15, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Zeta Global Holdings Corp. (NYSE:ZETA) Analyst/Investor Day October 8, 2025 8:30 AM EDT

Company Participants

Christopher Greiner - Chief Financial Officer
Steven Gerber - President
Matthew Mobley - Chief Operating Officer
Neej Gore - Chief Data Officer
Christian Monberg - CTO & Head of Product
Ed See - Chief Growth Officer
Jed Hartman - President of Activation Partnerships
David Steinberg - Co-Founder, Chairman of the Board & CEO
Pamela Lord - President of Customer Relationship Management

Conference Call Participants

Marc Brodherson
Courtney Trudeau
Sudarshan Mandayam
Adam Potashnick
Scott Berg - Needham & Company, LLC, Research Division
Arjun Bhatia - William Blair & Company L.L.C., Research Division
Elizabeth Elliott - Morgan Stanley, Research Division
David Hynes - Canaccord Genuity Corp., Research Division
Terrell Tillman - Truist Securities, Inc., Research Division
Jackson Ader - KeyBanc Capital Markets Inc., Research Division
Madeline Brooks - BofA Securities, Research Division
Matthew Swanson - RBC Capital Markets, Research Division
Jason Kreyer - Craig-Hallum Capital Group LLC, Research Division

Conversation

Christopher Greiner
Chief Financial Officer

Good morning, and thank you for joining us today, obviously, in person as well as those virtually. We have an exciting and informative day planned for you. We have new product releases, new members of management, customers and marketing experts you'll be able to hear from and engage with.

New structural views of where we believe we can take our adjusted EBITDA margins and free cash flow margins while sustaining our organic at least 20% revenue growth rate and new financial metrics that both underpin past performance as well as our future expectations, all intended to demonstrate the theme of today's Investor Day, a theme that's been entirely generated from your feedback.

They can be boiled down to three areas: First, durability, the durability of Zeta's proprietary data, our competitive advantages and our revenue growth rates, the predictability of our business around the ROI that we generate for our customers as well as the consistency of

Recommended For You

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

October 08, 2025 8:53 PM EDT | Source: Lion One Metals Limited
North Vancouver, British Columbia--(Newsfile Corp. - October 8, 2025) - Lion One Metals Limited (TSXV: LIO) (OTCQX: LOMLF) ("Lion One" or the "Company") is pleased to announce that in response to further investor demand, the Company intends to complete a non-brokered private placement (the "Sidecar Private Placement") of up to 21,875,000 units (the "Offered Units") at a price of $0.32 per Offered Unit for further gross proceeds of up to $7,000,000. The Sidecar Private Placement is being completed in addition to the Company's previously announced non-brokered private placement for gross proceeds of $25,000,000 pursuant to the listed issuer financing exemption available under National Instrument 45-106 - Prospectus Exemptions (the "LIFE Offering").

The Offered Units will be issued on the same financial terms as those units issued pursuant to the LIFE Offering. Each Offered Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of $0.42 for a period of three years from the date of issuance.

The Company initially announced the LIFE Offering on September 9, 2025 and closed the first tranche of the LIFE Offering on September 24, 2025 for gross proceeds of $18,715,153. The Company expects to close the second tranche of the LIFE Offering on or about October 15, 2025 and to close the Sidecar Private Placement on or about October 21, 2025.

The Company intends to use the net proceeds from the Sidecar Private Placement to fund the development of the Company's 100% owned and fully permitted high grade Tuvatu Gold Project, repayment of principal and interest for the Company's loan facility with Nebari, and for working capital purposes.

Closing of the Sidecar Private Placement is subject to certain customary conditions including receipt of all necessary approvals, including satisfaction of listing conditions of the TSX Venture Exchange ("TSX-V"). The Sidecar Private Placement may be closed in one or more tranches. The securities offered under the Sidecar Private Placement will be issued pursuant to applicable exemptions under National Instrument 45-106 - Prospectus Exemptions and will be subject to a statutory hold period of four months and one day following issuance of the Offered Units. Securities issued under the LIFE Offering will not be subject to Canadian resale restrictions in accordance with applicable Canadian securities laws.

The Company may pay finders' fees in connection with the Sidecar Private Placement, as permitted by applicable securities laws and the rules of the TSX-V. The finders' fees will consist of cash commissions equal to up to 8% of the gross proceeds raised from purchasers introduced to the Company by eligible finders and finder warrants equal to up to 8% of the aggregate number of Offered Units sold to purchasers introduced to the Company by eligible finders. Each finders warrants will entitle the holder to purchase one Common Share at a purchase price of $0.32 per finders warrant exercisable for a period of 24 months after the issuance of such finder warrants.

With respect to the LIFE Offering, there is an amended offering document relating to the LIFE Offering (the "Second Amended Offering Document") that can be accessed under the Company's profile at www.sedarplus.ca and at https://liononemetals.com. Prospective investors in the LIFE Offering should read the Second Amended Offering Document before making an investment decision.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any Common Shares in the United States. The securities to be sold in the LIFE Offering have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Lion One Metals Limited

Lion One Metals is an emerging Canadian gold producer headquartered in North Vancouver BC, with new operations established in late 2023 at its 100% owned Tuvatu Alkaline Gold Project in Fiji. The Tuvatu project comprises the high-grade Tuvatu Alkaline Gold Deposit, the Underground Gold Mine, the Pilot Plant, and the Assay Lab. The Company also has an extensive exploration license covering the entire Navilawa Caldera, which is host to multiple mineralized zones and highly prospective exploration targets.

On behalf of the Board of Directors of
Lion One Metals Limited

"Walter Berukoff"
Chairman of the Board

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. All statements other than statements of historical fact may be forward‐looking statements or information. Forward-looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company. Forward-looking statements made in this news release include statements regarding anticipated completion of the Sidecar Private Placement and the LIFE Offering and the proposed use of proceeds of the Sidecar Private Placement and LIFE Offering. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, with respect to the LIFE Offering and Sidecar Private Placement; debt settlement; the conditions of the financial markets; availability of financing; timeliness of completion of the Sidecar Private Placement and LIFE Offering; the timing of TSX-V approval; with respect to the use of proceeds, the sufficiency of the proceeds; the speculative nature of mineral exploration and development; fluctuating commodity prices; and competition, as described in more detail in our recent securities filings available at www.sedarplus.ca. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269755

In the latest close session, Array Technologies, Inc. (ARRY - Free Report) was down 2.75% at $8.48. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day.

The company's stock has climbed by 10.1% in the past month, exceeding the Oils-Energy sector's gain of 3.53% and the S&P 500's gain of 3.68%.

The investment community will be closely monitoring the performance of Array Technologies, Inc. in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $0.21, reflecting a 23.53% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $313.3 million, reflecting a 35.39% rise from the equivalent quarter last year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.67 per share and revenue of $1.2 billion. These totals would mark changes of +11.67% and +31.29%, respectively, from last year.

Investors should also take note of any recent adjustments to analyst estimates for Array Technologies, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.24% lower. Array Technologies, Inc. presently features a Zacks Rank of #3 (Hold).

Valuation is also important, so investors should note that Array Technologies, Inc. has a Forward P/E ratio of 13.06 right now. This signifies a discount in comparison to the average Forward P/E of 17.18 for its industry.

We can additionally observe that ARRY currently boasts a PEG ratio of 0.69. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Solar industry was having an average PEG ratio of 0.81.

The Solar industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 46, which puts it in the top 19% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Ouster, Inc. (OUST - Free Report) ended the recent trading session at $30.65, demonstrating a -6.24% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.58%.

The company's stock has climbed by 14.66% in the past month, exceeding the Computer and Technology sector's gain of 6.37% and the S&P 500's gain of 3.68%.

Analysts and investors alike will be keeping a close eye on the performance of Ouster, Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.43, signifying a 20.37% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $36.75 million, indicating a 30.88% increase compared to the same quarter of the previous year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$1.58 per share and a revenue of $144.25 million, indicating changes of +24.04% and +29.84%, respectively, from the former year.

Investors should also note any recent changes to analyst estimates for Ouster, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Ouster, Inc. boasts a Zacks Rank of #2 (Buy).

The Electronics - Miscellaneous Components industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 41, positioning it in the top 17% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

CRH (CRH - Free Report) ended the recent trading session at $117.85, demonstrating a +1.3% change from the preceding day's closing price. This change outpaced the S&P 500's 0.58% gain on the day.

Coming into today, shares of the building material company had gained 5.08% in the past month. In that same time, the Construction sector lost 3.22%, while the S&P 500 gained 3.68%.

Market participants will be closely following the financial results of CRH in its upcoming release. The company is forecasted to report an EPS of $2.18, showcasing a 15.96% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $11.24 billion, indicating a 6.9% growth compared to the corresponding quarter of the prior year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.57 per share and a revenue of $37.74 billion, representing changes of +3.34% and +6.1%, respectively, from the prior year.

Investors should also pay attention to any latest changes in analyst estimates for CRH. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.92% lower. CRH is holding a Zacks Rank of #3 (Hold) right now.

Looking at its valuation, CRH is holding a Forward P/E ratio of 20.88. Its industry sports an average Forward P/E of 19.43, so one might conclude that CRH is trading at a premium comparatively.

One should further note that CRH currently holds a PEG ratio of 1.65. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Building Products - Miscellaneous industry stood at 1.86 at the close of the market yesterday.

The Building Products - Miscellaneous industry is part of the Construction sector. This group has a Zacks Industry Rank of 154, putting it in the bottom 38% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

In the latest close session, VirTra, Inc. (VTSI - Free Report) was up +2.13% at $6.23. This move outpaced the S&P 500's daily gain of 0.58%.

The company's stock has climbed by 6.83% in the past month, exceeding the Aerospace sector's gain of 5.47% and the S&P 500's gain of 3.68%.

The investment community will be paying close attention to the earnings performance of VirTra, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be $0.05, reflecting no change from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.48 million, showing steadiness compared to the year-ago quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.33 per share and a revenue of $29.79 million, signifying shifts of +175% and +10.12%, respectively, from the last year.

It's also important for investors to be aware of any recent modifications to analyst estimates for VirTra, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. VirTra, Inc. presently features a Zacks Rank of #3 (Hold).

In the context of valuation, VirTra, Inc. is at present trading with a Forward P/E ratio of 18.49. This expresses no noticeable deviation compared to the average Forward P/E of 18.49 of its industry.

The Electronics - Military industry is part of the Aerospace sector. At present, this industry carries a Zacks Industry Rank of 94, placing it within the top 39% of over 250 industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Inventiva S.A. (NASDAQ:IVA) Analyst/Investor Day October 8, 2025 11:30 AM EDT

Company Participants

Mark Pruzanski
Andrew Obenshain - CEO & Director
Jason Campagna - President of Research and Development & Chief Medical Officer
Martine Zimmermann - Executive VP of Regulatory Affairs & Quality Assurance

Conference Call Participants

William Alazawi
Arun Sanyal
Nezam H. Afdhal
Henry E. Chang
Seamus Fernandez - Guggenheim Securities, LLC, Research Division
Yasmeen Rahimi - Piper Sandler & Co., Research Division
Ritu Baral - TD Cowen, Research Division
Edward Nash - Canaccord Genuity Corp., Research Division
Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division
Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division
Rami Katkhuda - LifeSci Capital, LLC, Research Division
Antonio Arce - WestPark Capital, Inc., Research Division

Presentation

Mark Pruzanski

Okay. Why don't we kick things off. Hi, everyone. I'm Mark Pruzanski, I'm the Chairman of the Board of Inventiva and welcome to our investor event. We're going to be telling you today about the next and hopefully best-in-category oral therapy to get to patients with MASH, lanifibranor. We're going to be making forward-looking statements. Here's the agenda.

It's going to be pretty packed, and I'm going to get out of your way and introduce you to Andrew in a minute followed by 3 well-known, key opinion-leading hepatologists in the MASH space. And then we will a panel discussion with some of the senior management team and time for Q&A at the end. So I've been involved with Inventiva for the better part of the year. And it's been a momentous year. All of you know that we just about a year ago raised a $400-plus million pipe, which positioned the company very well with respect to the enrollment of the global Phase III NATiV3 trial.

We double-clicked to accelerate enrollment and over enrolled the study, which we announced in April of this year. And then

Recommended For You

OKLAHOMA CITY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Murphy Law Firm is investigating claims on behalf of all individuals whose personal and confidential information was compromised in the data breach involving AppFolio, Inc. To join the class action lawsuit, visit our site HERE.

On or around August 22, 2025, AppFolio, Inc. (“AppFolio”) became aware of a security incident affecting Salesloft, a provider of sales enablement software and one of AppFolio’s vendors. Based on a subsequent forensic investigation, AppFolio determined that cybercriminals infiltrated this inadequately secured network and gained access to AppFolio’s files. The investigation further determined that, through this infiltration, cybercriminals accessed and/or acquired files containing the sensitive personal information of tens of thousands of individuals.

The information exposed in the data breach includes, but is not limited to:

NamesSocial Security numbers If you received notice of the AppFolio and Salesloft data breach or if your personal information was compromised in the breach, please visit our site HERE. Murphy Law Firm is evaluating legal options, including a potential class action lawsuit, to recover damages on behalf of individuals who were affected by the AppFolio data breach.

As a result of the data breach, these individuals’ personal and highly sensitive information may be in the hands of cybercriminals who can place the information for sale on the dark web or use the information to perpetrate identity theft.

To join a class action lawsuit, click HERE

Murphy Law Firm specializes in data breach class actions, consumer class actions, and federal securities class actions. The firm has extensive experience in securing highly favorable recoveries for its clients.

Contact:
Murphy Law Firm
[email protected]

Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression

, /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced new data for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) will be highlighted at the upcoming American Academy of Ophthalmology Annual Meeting (AAO 2025), October 18-20, in Orlando, Fla.

The data feature long-term safety and efficacy results from the GATHER2 open-label extension study, real-world evidence on treatment patterns and safety of IZERVAY in the U.S., and the latest findings on a structure-function link in GA via ellipsoid zone integrity and low-luminance deficit.

Marci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas Pharma
"Astellas continues to advance understanding of geographic atrophy (GA) through new data that deepen insights into disease progression and treatment. We are committed to partnering with the retina community to continue driving innovation that improves outcomes for patients with GA."

Overview of Astellas Presentations at AAO 2025

Presentation Title

Presenter

Presentation Details

Avacincaptad Pegol for GA: 3-year
Results from the GATHER2 Open-Label
Extension Trial

A. Khanani     

Type: Oral

Presentation Number: TBD

Date: Oct 17, 2025

4:58-5:05 PM ET

Treatment Patterns and Safety of
Avacincaptad Pegol in Real-World
Patients With GA

D. Borkar

Type: Poster Panel Discussion

Poster Number: PO078

Date: Oct 17, 2025

2:30-3:00 PM ET

Structure‒Function Link of Ellipsoid Zone
Integrity and Low Luminance Deficit in
Avacincaptad Pegol-Treated Eyes With
Geographic Atrophy

R. Downes

Type: On Demand Poster

Poster Number: PO696

IZERVAY is approved for the treatment of GA in the United States and Japan, and remains investigational in other countries and regions.

About IZERVAY™ (avacincaptad pegol intravitreal solution)

IMPORTANT SAFETY INFORMATION AND USE

Do NOT receive IZERVAY if you: 

Have an infection in or around your eye 
Have active swelling in or around your eye that may include pain and redness 

IZERVAY can cause serious side effects: 

Eye injections like the one for IZERVAY can cause an eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment). 
Call your healthcare provider right away if you have redness of the eye, eye pain, increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small specks floating in your vision, flashes of light, or increased sensitivity to light. 
There is a risk of developing wet AMD with IZERVAY. You should report any symptoms (visual distortions such as straight lines seeming bent, deterioration in vision, dark spots, loss of central vision) to your healthcare provider to monitor. 
IZERVAY may cause a temporary increase in eye pressure after the injection. Your healthcare provider will monitor this after each injection. 

Before receiving IZERVAY tell your healthcare provider about all of your medical conditions including if you: 

Have a history of seeing flashes of light or small specks floating in your vision and if you have a sudden increase of size and number of these specks. 
Have high pressure in the eye or if you have glaucoma. 
Are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about any medicine you take. 

What should I avoid while receiving IZERVAY? 

Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently. 

What are the most common side effects of IZERVAY? 

Blood in the white of the eye 
Increase in eye pressure 
Blurred vision 
Wet age-related macular degeneration 

These are not all the possible side effects of IZERVAY. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for more information.

What is IZERVAY™?
IZERVAY (avacincaptad pegol intravitreal solution) is a prescription eye injection, used to treat geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD). 

About Geographic Atrophy
Age-related macular degeneration (AMD) is the major cause of moderate and severe loss of central vision in aging adults, affecting both eyes in the majority of patients. The macula is a small area in the central portion of the retina responsible for central vision. As AMD progresses, the loss of retinal cells and the underlying blood vessels in the macula results in marked thinning and/or atrophy of retinal tissue. Geographic atrophy, associated with AMD, leads to further irreversible loss of vision in these patients.

About the GATHER Clinical Trials
IZERVAY met its primary endpoint in the GATHER1 (NCT02686658) clinical trial and the GATHER2 (NCT04435366) clinical trial, both of which were randomized, double-masked, sham-controlled, multicenter Phase 3 clinical trials. These trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either IZERVAY 2 mg or sham monthly. There were 286 participants enrolled in GATHER1 and 448 participants enrolled in GATHER2. The primary efficacy endpoints in both pivotal studies were based on GA area measured by fundus autofluorescence at three time points: baseline, month 6, and month 12. Safety was evaluated in over 700 patients with GA across the two trials.

In year 2 of the GATHER2 study, patients treated with IZERVAY in year 1 were re-randomized to receive either IZERVAY dosed monthly (EM, n=96) or every other month (EOM, n=93); patients who received sham in year 1 continued to receive sham in year 2 (n=203).

About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

SOURCE Astellas Pharma Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Key Takeaways The 2025 Wall Street narrative has shifted dramatically from panic to bubble fears.Legendary investor Paul Tudor Jones made headlines when he compared the 2025 market to 1999.A rate cut with stocks at highs, muted sentiment, and further AI expansion suggest a market with legs.
2025 is a prime example of how dynamic the Wall Street narrative can be and how price action can change that narrative. A mere six months ago, Wall Street was in panic mode as President Trump unveiled his ‘Liberation Day’ tariff policy, an economic strategy an American President had not attempted in a century. At the time, many Wall Street investors viewed President Trump’s tariffs as economic suicide, with some even predicting that another “Black Monday” would occur (referring to the day the S&P 500 Index dropped 20% in a single day on October 19, 1987).

Fast forward to the present day, and the Nasdaq Composite is up 50% over the past six months, driven by AI enthusiasm. Today, the Wall Street narrative has done a 180-degree turn from market crash fears to market bubble fears. Let’s use the internet bubble as a potential precedent to explore the current market environment and determine where we stand:

Paul Tudor Jones 1999 Bombshell Comparison

In a recent interview on CNBC’s ‘Squawk Box,’ billionaire and legendary investor Paul Tudor Jones dropped a bombshell, saying that the current market “feels exactly like 1999” and that “investors need to position themselves like it’s October 1999.” If Paul Tudor Jones’ analysis is correct, there is plenty of meat left on the bone for tech investors as the Nasdaq doubled from 1999 to 2000. Not only does Tudor Jones see the 2025 market similar to 1999, but he also believes the current market may end up being more powerful.

Image Source: TradingView

The 1999/2025 Market PrecedentPaul Tudor Jones is no stranger to using market precedents to make bold market predictions. In 1987, he famously predicted the “Black Monday” crash by utilizing an overlay chart that compared the 1987 market to 1929. After shorting the market, a young Paul Tudor Jones and his firm returned 125% in 1987, netting approximately $100 million. Overlay a 1999 and 2025 chart, and the price action looks eerily similar.

Image Source: BarChart

Meanwhile, the current bull market (which started after the tariff madness dissipated) is only a handful of months old. Historically, the average bull market is ~4 years.

Interest Rate Cuts at New Highs = Rocket FuelBeyond the hype surrounding AI, the Federal Reserve is adding fuel to the fire. At the last Fed meeting, Chair Jerome Powell cut interest rates as the S&P 500 reached a new high. The Federal Reserve has cut interest rates 12 times when the S&P 500 Index was within 1% of its all-time high. The market was higher one year later all 12 times, with a median return of 15%, according to JPMorgan ((JPM - Free Report) ) research.

Image Source: Carson Investment Research, @ryandetrick

AI: Beyond LLMs and into the Software LayerUntil now, most AI performance has been concentrated among semiconductor players like Advanced Micro Devices ((AMD - Free Report) ), infrastructure providers like CoreWeave ((CRWV - Free Report) ), and data center energy companies like Bloom Energy ((BE - Free Report) ). However, AI winners are beginning to proliferate from pure-play stocks into other tech areas, such as software stocks. For instance, Figma ((FIG - Free Report) ) and Shopify ((SHOP - Free Report) ) are rising this week after signing deals with OpenAI, the parent company of ChatGPT. The FIG/OpenAI integration will enable users to design tasks with ChatGPT conversations. Meanwhile, SHOP’s partnership will allow ChatGPT users to bypass the traditional e-commerce journey and purchase products straight from the LLM. This collaboration positions Shopify merchants to reach a vast new audience and capitalize on the growing field of conversational commerce.

Animal Spirits Yes, Euphoria NoAny time stocks are up 50% in six months, it’s hard for investors to argue that the animal spirits have been unleashed. Nevertheless, several data points suggest that the current market is far from euphoric. For instance, according to the AAII Sentiment Survey, investor sentiment is not overheated. Bullish sentiment stands at 42.9%, neutral sentiment at 17.9%, and bearish sentiment remains elevated at 39.2%.

Image Source: AAII

Additionally, there is a substantial amount of “dry powder” on the sidelines, with a record $7 trillion in low-risk money market funds. As stocks continue to rise, investors are likely to suffer from “the fear of missing out,” eventually removing funds from these safe havens and into the stock market, adding fuel to the fire.

Valuations are High but Likely to Stretch HigherA key concern among investors is that 2025 valuations are too rich. While the S&P’s current P/E ratio of 23x is elevated compared to historical norms, it pales in comparison to the 2000 peak, which exceeded 40x. Investors must understand that Wall Street is willing to pay higher valuations for high-tech, innovative companies like the current AI leaders.

Image Source: Robert Shiller

Bottom Line

The 2025 bull market is unusually bullish. Although stocks experienced a tremendous run since the ‘Liberation Day’ lows, several key data points suggest that the Nasdaq could still double from here.

By Reuters

October 8, 202511:35 PM UTCUpdated ago

A Microsoft logo is seen in Los Angeles, California U.S. November 7, 2017. REUTERS/Lucy Nicholson Purchase Licensing Rights, opens new tab

Oct 8 (Reuters) - Microsoft

(MSFT.O), opens new tab is partnering with Harvard Medical School to enhance its Copilot AI assistant with health content, as part of a broader effort to reduce its dependence on ChatGPT-maker OpenAI, the Wall Street Journal reported on Wednesday.

A major update of Copilot scheduled for release as soon as this month will be the first to reflect a new collaboration between Microsoft and Harvard Medical School, the report said, citing people familiar with the matter.

Sign up here.

Reuters could not immediately verify the report.

Microsoft and Harvard did not immediately respond to requests for comment.

Reporting by Rishabh Jaiswal and Rajveer Singh Pardesi in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles., opens new tab

ARYZTA AG - Special Call

Company Participants

Paul Meade - Head of Communications
Urs Jordi
Martin Huber - Group Chief Financial Officer

Conference Call Participants

Joern Iffert - UBS Investment Bank, Research Division
Jon Cox - Kepler Cheuvreux, Research Division

Presentation

Operator

Good morning, ladies and gentlemen, and welcome to this ARYZTA update call. The call will have opening remarks by ARYZTA management and followed by Q&A. This call is being recorded. Now, I'd like to hand over to Paul Meade, Head of Investor Relations, to open the call. Please go ahead.

Paul Meade
Head of Communications

Thanks, Laura. Good morning, all, and welcome to today's update. I'm joined today by our Chairman and Interim CEO, Urs Jordi; and our CFO, Martin Huber. I would just like to remind everyone that the normal forward-looking statement of risks and uncertainties applies to all of today's discussions. I would now hand over to Urs.

Urs Jordi

Thank you, Paul. Good morning to everybody for joining this call. You did receive our ad hoc statement today morning. I think the message is understood, and I think we go directly into Q&A, Paul.

Paul Meade
Head of Communications

That's fine. Laura, can you ask folks if they have any questions on the ad hoc on the announcements, please?

Question-and-Answer Session

Operator

[Operator Instructions] The first question comes from Jorn Iffert of UBS.

Joern Iffert
UBS Investment Bank, Research Division

Just to double check, can you hear me?

Urs Jordi

Yes.

Joern Iffert
UBS Investment Bank, Research Division

Just a couple of questions from my side. The first one would be, please, I would take them one by one, if it's okay. There's a quite significant deviation in the second half EBITDA year-over-year versus your guidance of around, what is it, 10% plus/minus at least. Where exactly is this deviation coming from? This would be my

Recommended For You

, /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or sold Cepton, Inc. (NASDAQ: CPTN) common stock between July 29, 2024 and January 6, 2025. Prior to its merger with Koito Manufacturing Co., Ltd., Cepton was an electronics company focused on the deployment of high performance, mass-market lidar technologies to deliver safety and autonomy across the Automotive and Smart Infrastructure markets. 

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Cepton, Inc. (CPTN) Misled Investors in Connection with the Company's Acquisition by Koito Manufacturing Co., Ltd.

The complaint alleges that in December 2023, Koito announced a bid to acquire Cepton for $3.17 per share in cash in a going private transaction. The transaction closed on January 7, 2025.

According to the complaint, defendants failed to disclose that: (i) Cepton had received a credible third-party bid valuing Cepton at more than double the Koito Acquisition; (ii) Cepton's Board of Directors failed to meaningfully explore the foregoing offer and failed to disclose its terms when recommending that Cepton's shareholders approve the Koito acquisition; and (iii) as a result, Cepton's shareholders were deprived of the opportunity to meaningfully consider whether to accept or reject the Koito acquisition.

What Now: You may be eligible to participate in the class action against Cepton, Inc. Shareholders who wish to serve as lead plaintiff for the class must file their papers with the court by December 8, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses. 

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. 

To be notified if a class action against Cepton, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome. 

SOURCE Robbins LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

CoreWeave Co-Founder and CEO Mike Intrator joins 'Mad Money' host Jim Cramer to talk quarterly results, the state of play in the AI space, recent acquisitions and more.

JPMorgan Chase & Co. (JPM - Free Report) closed the most recent trading day at $304.03, moving -1.19% from the previous trading session. This move lagged the S&P 500's daily gain of 0.58%.

Shares of the company witnessed a gain of 3.3% over the previous month, beating the performance of the Finance sector with its gain of 1.07%, and underperforming the S&P 500's gain of 3.68%.

Analysts and investors alike will be keeping a close eye on the performance of JPMorgan Chase & Co. in its upcoming earnings disclosure. The company's earnings report is set to go public on October 14, 2025. On that day, JPMorgan Chase & Co. is projected to report earnings of $4.83 per share, which would represent year-over-year growth of 10.53%. Simultaneously, our latest consensus estimate expects the revenue to be $44.66 billion, showing a 4.7% escalation compared to the year-ago quarter.

JPM's full-year Zacks Consensus Estimates are calling for earnings of $19.87 per share and revenue of $178.82 billion. These results would represent year-over-year changes of +0.61% and +0.71%, respectively.

Investors should also note any recent changes to analyst estimates for JPMorgan Chase & Co. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.14% higher. Currently, JPMorgan Chase & Co. is carrying a Zacks Rank of #3 (Hold).

Digging into valuation, JPMorgan Chase & Co. currently has a Forward P/E ratio of 15.49. This expresses a discount compared to the average Forward P/E of 16.79 of its industry.

It is also worth noting that JPM currently has a PEG ratio of 1.96. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Financial - Investment Bank stocks are, on average, holding a PEG ratio of 1.49 based on yesterday's closing prices.

The Financial - Investment Bank industry is part of the Finance sector. With its current Zacks Industry Rank of 28, this industry ranks in the top 12% of all industries, numbering over 250.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

, /PRNewswire/ -- NeoVolta Inc. (NASDAQ:NEOV) is moving quickly to scale its energy storage business, signing an asset purchase agreement for Neubau Energy's next-generation modular battery platform and adding Neubau's senior leadership team to its ranks. 

The transaction, finalized on October 1, 2025, is expected to close by October 15 and to be immediately accretive to both revenue and gross margins.

NeoVolta Expands Portfolio With Neubau Energy Acquisition, Targeting Higher Revenues and Margins

As part of the transaction, NeoVolta has appointed Amany Ibrahim as Chief Operating Officer and Thomas Enzendorfer as Chief Technology Officer. Michael Mendik, NeoVolta's previous COO, will remain with the company as Chief Product Officer.

Amany Ibrahim, co-founder and former Chief Strategy Officer at Neubau Energy, led product innovation and market expansion for its modular residential battery platform. She brings over a decade of operational experience in energy and infrastructure. Thomas Enzendorfer served as CEO of Neubau Energy in California and Managing Director in Vienna, overseeing solar manufacturing and distribution. His prior roles include Director of Solar Energy at Fronius USA and President of Soligent Distribution LLC.

A Platform Built for Speed

By integrating Neubau's modular energy storage technology, NeoVolta expects to accelerate its expansion across the residential storage market. Neubau's 30-minute installation systems will soon be available under the NeoVolta brand, cutting deployment costs by up to 75% and opening new channels for installers and electricians.

"Merging Neubau's talent and next-gen battery manufacturing platform is a significant milestone in executing our growth multi-channel strategy. As the transaction accelerates our residential energy storage market penetration, we expect it to be immediately accretive to revenue and gross margins," said Ardes Johnson, CEO of NeoVolta. "Neubau's technology portfolio and manufacturing know-how are expected to provide us tariff-free access to advanced battery technology. At Neubau, Amany has spearheaded strategy, product innovation, and market expansion and Thomas led manufacturing and distribution. We are excited they will strengthen our team and support our aggressive growth plans."

Deal Overview

The acquisition brings together Neubau's proprietary battery architecture and NeoVolta's growing distribution network, creating a platform designed for scale. Neubau's modular design, which is protected by more than a dozen patents, integrates inverters, batteries, and management software into a single, rapidly deployable system that one installer can set up in under 30 minutes.

Under the terms of the agreement, NeoVolta:

Paid $500,000 in cash and issued 200,000 restricted common shares at signing.
Will pay unit royalties of $10 per neuClick Battery Module sold for three years.
May issue up to 4 million additional restricted shares if Neubau-related revenue milestones are met before December 31, 2028.
NeoVolta expects the transaction to:

Strengthen its leadership with Neubau's senior executives joining key operational roles.
Reduce installation times by up to 75%, expanding access to new installer networks.
Add high energy-density ESS modules and modular battery patents to its portfolio.
Lessen exposure to 2026 tariffs through Neubau's Austrian manufacturing base.
Together, the integration is expected to accelerate NeoVolta's residential market reach, increase gross margins, and deepen the company's presence across both U.S. and international energy storage markets.

About Neubau Energy

Founded in 2023, Neubau Energy has developed one of the industry's most installer-friendly residential battery system with the highest energy density in its class. The company's truly modular architecture, protected by over a dozen patents, integrates batteries, inverter, battery management, and communications into a single unit that one person can install in under 30 minutes. The company's experienced team includes veterans from the energy storage, solar, and automotive industries who will continue driving innovation in operational and technology leadership roles as part of the combined organization. Neubau's Austrian manufacturing base provides a tariff-advantaged platform for the U.S. residential storage market. For more information visit: www.neubauenergy.com

About NeoVolta

NeoVolta is a leading innovator in energy storage solutions dedicated to advancing the future of clean energy. Founded to provide reliable, sustainable, and high-performance energy storage systems, the company has quickly established itself as a critical player in the industry. NeoVolta's flagship products are designed to meet the growing demand for efficient energy management in residential and commercial applications. With a focus on cutting-edge technology and strategic partnerships, NeoVolta is committed to driving progress in renewable energy and enhancing how the world stores and uses power. For more information visit: www.neovolta.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the acquisition of Neubau Energy assets, expected financial impacts, market opportunities, operational benefits, and anticipated closing timeline. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Such risks include, but are not limited to, the ability to complete definitive documentation, satisfaction of closing conditions, integration challenges, market acceptance of combined offerings, realization of anticipated synergies, and other risks detailed in NeoVolta's SEC filings. The company undertakes no obligation to update forward-looking statements except as required by law. For additional risk factors, see Item 1A "Risk Factors" in the Company's most recent Form 10-K and subsequent Form 10-Q filings with the SEC.

Contacts

Investors David Barnard, Alliance Advisors IR [email protected]

415-433-3777

Media Email: [email protected]

800-364-5464

Disclosure:

1) The author of the Article, or members of the author's immediate household or family, do not own any securities of the companies outlined in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by,  NeoVolta Inc. Market Jar Media Inc. was paid $1,500 USD for the production and publishing of this article by  NeoVolta Inc.'s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.'s engagement by NeoVolta Inc.'s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-neov. 

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use (https://pressreach.com/terms-of-use/) and full legal disclaimer as set forth here (https://pressreach.com/disclaimer/). This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities legislation, (collectively, "forward-looking statements"), which reflect management's expectations regarding  NeoVolta Inc.'s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as "predicts", "projects", "targets", "plans", "expects", "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to  NeoVolta Inc.'s industry; (b) market opportunity; (c)  NeoVolta Inc.'s business plans and strategies; (d) services that  NeoVolta Inc.. intends to offer; (e)  NeoVolta Inc.'s milestone projections and targets; (f)  NeoVolta Inc.'s expectations regarding receipt of approval for regulatory applications; (g)  NeoVolta Inc.'s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h)  NeoVolta Inc.'s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute  NeoVolta Inc.'s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c)  NeoVolta Inc.'s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e)  NeoVolta Inc.'s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of  NeoVolta Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a)  NeoVolta Inc.'s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact  NeoVolta Inc.'s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing  NeoVolta Inc.'s business operations (e) NeoVolta Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law,  NeoVolta Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does  NeoVolta Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither  NeoVolta Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of  NeoVolta Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of  NeoVolta Inc. or such entities and are not necessarily indicative of future performance of  NeoVolta Inc. or such entities.

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

Read more investing news on PressReach.com.

Subscribe to the PressReach RSS feeds:

Featured News RSS feed
Investing News RSS feed
Daily Press Releases RSS feed
Trading Tips RSS feed
Investing Videos RSS feed
Follow PressReach on Twitter

Follow PressReach on TikTok

Follow PressReach on Instagram

Subscribe to us on Youtube

Contact

Media
[email protected]

SOURCE NeoVolta Inc

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Vancouver, British Columbia, Canada – October 8, 2025 – TheNewswire - GOAT Industries Ltd. (the “Company” or “GOAT”) (CSE: GOAT) (OTCQB: BGTTF) (FWB: 26B.F) is pleased to announce that its common shares have been approved for trading on the OTCQB Venture Market (the “OTCQB”), operated by the OTC Markets Group, effective as of market open on October 9, 2025. The Company will continue to trade under the symbol “BGTTF” on the OTCQB and “GOAT” on the Canadian Securities Exchange (“CSE”).

The uplisting to the OTCQB Venture Market marks a significant milestone in GOAT’s capital markets strategy and underscores the Company’s commitment to transparency, governance, and growth. This achievement enhances GOAT’s visibility and credibility through compliance with U.S. securities regulations and ongoing disclosure obligations, while improving liquidity and accessibility for U.S. investors by expanding market depth and trading volume. The OTCQB, recognized as a premier venture market for early-stage and developing companies that meet stringent financial reporting and governance standards, provides GOAT with a platform that promotes greater transparency, stronger corporate governance, and the ability to attract both institutional and retail investors across North America. Collectively, these benefits reinforce GOAT’s long-term growth objectives as the Company continues to build shareholder value and strengthen its presence in North American capital markets.

“Achieving OTCQB status is a significant milestone for GOAT,” said Kevin Cornish, Interim CEO. “This uplisting reflects our commitment to transparency, governance, and growth. We believe trading on the OTCQB will improve market visibility, enhance liquidity, and provide broader access to U.S. investors as we continue to execute on our business strategy.”

Existing shareholders are not required to take any action. GOAT Industries will continue to trade on the CSE under the symbol “GOAT” and remains subject to all applicable CSE and Canadian securities regulations.

ABOUT GOAT INDUSTRIES LTD.

GOAT is an investment issuer focused on investing in high-potential companies operating across a variety of industries and sectors. The goal of the Company is to generate maximum returns from its investments.

For more information about the Company, please visit https://www.goatindustries.co/. The Company’s final prospectus, financial statements and management's discussion and analysis, among other documents, are all available on its profile page on SEDAR+ at www.sedarplus.ca.

ON BEHALF OF THE BOARD OF DIRECTORS

Interim Chief Executive Officer                Kevin Cornish

Head Office                                Suite 2300, 550 Burrard Street, Vancouver, BC V6C 2B5

Telephone                                1-604-683-6498

Website                                www.goatindustries.co  

Email                                        [email protected]  

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation, including, but not limited to, statements regarding the Company’s uplisting to the OTCQB Venture Market, the potential benefits of such uplisting, the Company’s business objectives, growth strategies, market visibility, liquidity, and future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, risks relating to the Company’s ability to maintain compliance with the OTCQB and CSE listing requirements, market conditions, investor interest, and general business, economic, competitive, political, and social uncertainties. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Canada Goose (GOOS - Free Report) closed the most recent trading day at $13.72, moving -1.29% from the previous trading session. This change lagged the S&P 500's daily gain of 0.58%.

Heading into today, shares of the high-end coat maker had lost 6.65% over the past month, lagging the Retail-Wholesale sector's loss of 2.75% and the S&P 500's gain of 3.68%.

Market participants will be closely following the financial results of Canada Goose in its upcoming release. The company is expected to report EPS of -$0.05, down 225% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $208.8 million, reflecting a 6.36% rise from the equivalent quarter last year.

For the full year, the Zacks Consensus Estimates project earnings of $0.99 per share and a revenue of $1.05 billion, demonstrating changes of +23.75% and +8.22%, respectively, from the preceding year.

It is also important to note the recent changes to analyst estimates for Canada Goose. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Canada Goose currently has a Zacks Rank of #3 (Hold).

From a valuation perspective, Canada Goose is currently exchanging hands at a Forward P/E ratio of 14.11. This represents a discount compared to its industry average Forward P/E of 17.84.

Also, we should mention that GOOS has a PEG ratio of 1.04. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Retail - Apparel and Shoes stocks are, on average, holding a PEG ratio of 2.38 based on yesterday's closing prices.

The Retail - Apparel and Shoes industry is part of the Retail-Wholesale sector. Currently, this industry holds a Zacks Industry Rank of 72, positioning it in the top 30% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Emerson Electric (EMR - Free Report) closed at $132.94 in the latest trading session, marking a +1.1% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.58%.

Shares of the maker of process controls systems, valves and analytical instruments witnessed a loss of 0.42% over the previous month, trailing the performance of the Industrial Products sector with its gain of 0.74%, and the S&P 500's gain of 3.68%.

Analysts and investors alike will be keeping a close eye on the performance of Emerson Electric in its upcoming earnings disclosure. On that day, Emerson Electric is projected to report earnings of $1.62 per share, which would represent year-over-year growth of 9.46%. Meanwhile, the latest consensus estimate predicts the revenue to be $4.9 billion, indicating a 5.98% increase compared to the same quarter of the previous year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6 per share and revenue of $18.06 billion, indicating changes of +9.29% and 0%, respectively, compared to the previous year.

Investors should also note any recent changes to analyst estimates for Emerson Electric. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.06% increase. Emerson Electric is currently sporting a Zacks Rank of #3 (Hold).

In terms of valuation, Emerson Electric is currently trading at a Forward P/E ratio of 20.33. Its industry sports an average Forward P/E of 23.03, so one might conclude that Emerson Electric is trading at a discount comparatively.

We can also see that EMR currently has a PEG ratio of 2.29. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Manufacturing - Electronics stocks are, on average, holding a PEG ratio of 1.92 based on yesterday's closing prices.

The Manufacturing - Electronics industry is part of the Industrial Products sector. With its current Zacks Industry Rank of 151, this industry ranks in the bottom 39% of all industries, numbering over 250.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.